Banner GPTW 2024_25
640px-World_Health_Organisation_headquarters,_Geneva,_north_and_west_sides

WHO recommends COVID-19 Booster

World Health Organization recommends administration of additional booster doses to population with highest risk

Read here

GEMCOVAC OM EUA post_Final

GEMCOVAC®-OM – Gennova’s booster vaccine for COVID-19

 GEMCOVAC®-OM is an mRNA based Omicron-specific booster vaccine for the prevention of COVID-19 in individuals 18 years of age and older who have received either COVAXIN® or COVISHIELD™ as primary vaccination.

Information for Healthcare Professionals

General information

Transforming Healthcare

One of our greatest assets is our appreciation and understanding of the complexity of a problem and dedicated focus to develop a long lasting solution instead of looking for a quick fix. We realized early on that we will not be able to develop, deliver and survive in the competitive market of biotechnology if we do not innovate across all the required scientific platforms. This is what separates us from the rest of the traditional biotechnology companies interested in making biosimilar.

Why-How-What

Company Highlights

Gene to Market

  • 9 Commercialized
    Bio-therapeutics
  • 3 products – market leader in India
  • 2 novel products

Platform Technology

  • Patented manufacturing process
  • Readily scalable
  • AI guided innovation in
    Bio-manufacturing

Potential

  • 2 patents with market exclusivity
  • Unmet market need
  • Facility under development as per USFDA norms
  • Global clinical trials for 3 products in next 12-18 months
  • Quick launch in global market

Team

  • A strong leadership team, experienced in successful global collaboration and taking product from lab to market

Pipeline

  • Biologics
  • Vaccines
  • Next-Gen therapeutics

Product Milestones

Infrastructure

Other than our marketing strategies our investment in the technological development of the infrastructure gives us an edge over others. We have experience and expertise that allows us to develop innovative and cost effective products because of the cutting edge technology backed by research.

Global Collaborations

“Many factors play an important role in the process of Transforming Healthcare, and one of the most important is that we cannot innovate in isolation. We have to have collaborations.”

– Dr. Sanjay Singh, CEO, Gennova Biopharmaceuticals Ltd.

Gene to Market

We have a team of experienced and capable scientists and technocrats who have developed capabilities across scientific, manufacturing, regulatory, clinical and business arenas that have made it successful in the Indian market.
The experience and capabilities will facilitate the expansion of business in the global market for our current and pipeline products.